PDC

Across TCGA pan-cancer cohorts, PDC Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDC data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PDC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDC expression acts as an unfavorable survival marker.

KIRC, SKCM, and GBM are the cancer types where PDC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.203	0.789	.009	24	view →
SKCM	DFS	Median	IV	0.026	0.477	<.001	13	view →
GBM	OS	Median	All	0.005	0.416	<.001	12	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDC–KIRC (OS)

Open the KIRC breakdown →